AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Thursday 19 November 2026
News from the 24 hours to Thursday morning, 19 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mainly about the extended Tempus AI data agreement, US approval of a new Imfinzi bladder cancer regimen and a letter of intent between its Indian arm and Strand Life Sciences. A supportive broker view and a rebound after results add to the positive lean, though one report noted share price weakness.
What drove it
- Imfinzi bladder approval
- Tempus AI deal extension
- India partnership
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Fri 13 Nov | +5.3 | 8 |
| Sat 14 Nov | +5.5 | 39 |
| Sun 15 Nov | +7.5 | 9 |
| Mon 16 Nov | +4.5 | 6 |
| Tue 17 Nov | +9.7 | 45 |
| Wed 18 Nov | +7.0 | 29 |
| Thu 19 Nov | +5.5 | 23 |
8 stories · 23 headlines · strongest first
Pharma and healthcare on 19 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca pledges $200m to Tempus AI as their agreement is extended +4.510 headlines today · Outlets report a five-year extension through 2031. | ||
| +5.0 | Services contract prolonged for several years. | |
| +5.0 | Oncology agreement extended, showing continued investment. | |
| +5.0 | Sizeable multi-year data commitment supports oncology pipeline work. | |
| +5.0 | Data partnership with AI firm continues, supporting oncology research. | |
| +5.0 | Oncology data deal renewed with large commitment. | |
| +4.7 | Partnership prolonged with five-year funding commitment. | |
| +4.2 | Amended deal includes new multi-year spending commitment. | |
| +4.2 | Services agreement extended. | |
| +3.3 | Formal amendment to existing services contract. | |
| +3.3 | Contract amendment continues existing relationship. | |
| Strand Life Sciences and AstraZeneca Pharma India sign letter of intent +3.75 headlines today · 15 in all, since 18 November · Outlets report an LoI to explore healthcare collaboration. | ||
| +6.7 | Shares gained after the Indian tie-up news. | |
| +3.3 | Indian arm signs preliminary agreement to explore healthcare collaboration; small positive. | |
| +3.3 | Indian arm signs letter of intent for healthcare partnership. | |
| +3.3 | Indian unit and Strand to explore collaboration. | |
| +3.3 | Indian unit explores healthcare tie-up via non-binding letter. | |
| FDA approves Imfinzi regimen for bladder cancer +10.02 headlines today · 17 in all, since 14 November · Reports say the FDA cleared the Imfinzi bladder regimen. | ||
| +8.3 | Regulatory clearance for new use of key cancer drug. | |
| +8.3 | Approval of new bladder cancer treatment regimen. | |
| AstraZeneca share price moves +1.32 headlines today · Pieces cover a rebound this week and selling pressure near support. | ||
| +7.5 | Shares recovering following better-than-expected results. | |
| −5.0 | Share price weakness under selling pressure. | |
| Jefferies raises AstraZeneca target, keeps Buy +9.21 headline today · 2 in all, since 18 November · Jefferies believes AstraZeneca can achieve its $80bn sales goal. | ||
| +9.2 | Broker supportive and sees long-term revenue ambition as achievable. | |
| Rhythm Pharma bidding war speculation +2.51 headline today · Seeking Alpha discusses a possible AstraZeneca/Lilly bid. | ||
| +2.5 | Speculation about possible bid interest in a biotech; uncertain, mildly positive. | |
| Summit starts sixth Phase III ivonescimab trial against Imfinzi −2.51 headline today · Summit Therapeutics has begun a trial of ivonescimab compared with Imfinzi in lung cancer at stage III. | ||
| −2.5 | Rival trial targets head-to-head comparison with its lung cancer drug. | |
| AstraZeneca signs cloud ERP deal with SAP +2.71 headline today · 7 in all, since 15 November · Coverage notes deeper SAP cloud ties. | ||
| +1.7 | Deepening cloud software relationship; minor operational story. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.